Beth Snyder Bulik

Physicians prefer simple and clear messages from pharma advertisers, according to a new survey, and even they are confused by some ads.

Pfizer, Eli Lilly, Sanofi and Johnson & Johnson chimed in on the federal government’s plan to tag pharma TV ads with drug prices.

Innovation challenges continue to grow, but don't worry about brain drain. There are plenty of ideas still to go around.

Advocacy groups and pharma companies often work hand in hand, but this year saw some of the shine wear off.

In this issue, FiercePharmaMarketing looks back—and forward—to the focal points and features of 2018 that will keep trending in 2019.

Pharma's push in cancer marketing isn't done yet. Expect more ads across the media landscape as new cancer-fighters come to market.

Lawmakers on both sides of the aisle refuse to let go of the proposal to force drug pricing into consumer advertising, but they're not the only ones.

As patients continue taking a more active role in healthcare, pharma's interest in digital therapeutics, already on a roll, will only accelerate.

Chief digital officers in pharma are here to stay as they transform business and marketing practices.

Johnson & Johnson launched new print and online ad this week in defense of its flagship baby powder after damaging news reports.